Annotation Detail

Information
Associated Genes
MMP2
Associated Variants
MMP2 SERUM LEVELS
MMP2 SERUM LEVELS
Associated Disease
brain glioma
Source Database
CIViC Evidence
Description
Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas. Results were validated in a separate retrospective cohort (n = 50) and also tested in patients treated with cytotoxic agents without bevacizumab (n = 34). MMP2 level was correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005) in the discovery and validation cohorts but not in patients treated without bevacizumab.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1158
Gene URL
https://civic.genome.wustl.edu/links/genes/3549
Variant URL
https://civic.genome.wustl.edu/links/variants/487
Rating
2
Evidence Type
Predictive
Disease
Brain Glioma
Evidence Direction
Supports
Drug
Bevacizumab
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
24327581
Drugs
Drug NameSensitivitySupported
BevacizumabSensitivitytrue